This research aims to investigate the reactogenicity of mRNA-based COVID-19 vaccines and identify factors influencing immune response.
Randomized trial design assessing vaccine reactogenicity among varied populations.
Participants received mRNA vaccines and reported adverse events following immunization.
Data on immune response was collected and analyzed.
High rates of mild to moderate reactogenicity observed, with younger individuals reporting more adverse events.
Reactogenicity correlates with immune response levels, showing significant variation across demographics.
Abstract
Kimberly G. Blumenthal, MD, MSc; Lacey B. Robinson, MD, MPH; Carlos A. Camargo Jr, MD, DrPH; Erica S. Shenoy, MD, PhD; Aleena Banerji, MD; Adam B. Landman, MD; Paige Wickner, MD, MPH
问 AI
Like
Bookmark
Share
View Full Paper
问 AI
Like
Bookmark
Share
View Full Paper
Cite This Study
Chapin-Bardales et al. (Mon,) studied this question.